Study the ENT Manifestations of Covid-19 Patients, Aden, Yemen

Saleh Mohamed Abobaker Alshaiby

Associate Professor of ENT, Department of Special Surgery, Faculty of Medicine, University of Aden, Yemen

DOI: https://doi.org/10.52403/ijshr.20221027

ABSTRACT

Objective: To study and document the ENT manifestations of covid-19 infection of patients in Aden, Yemen

Materials and method: This was a retrospective descriptive study, in which we reviewed the medical records of 81 patients with Covid-19 seen at *Covid-19* Treatment Center at Al-Gamhoria Teaching Hospital in Aden during the period April 2020 to March 2021.

The Fisher test was used to determine whether the difference between means and values are significant. A p-value <0.05 was considered statistically significant.

Results: Out of 81 patients, 52 patients were males (64.2%) and 29 patients (35.8%) were females and the mean age was 40.2 ± 13.9 years. The mean age of male patients was 41.8 ± 13.6 years while for females was 37.3 ± 14.5 years. The age ranged between 18 to 66 years; the association between means is statistically significant, in addition the age group < 45 years represented 59.3%.

Anosmia-dysgeusia with sore throat and pharyngeal erythema, were the most common ENT manifestations, 77.8%, and 77.8% respectively. The male patients had a higher probability of developing ENT manifestations.

The relation between anosmia-dysgeusia and sex was statistically significant (p < 0.05).

The manifestation of anosmia-dysgeusia more common among patients of the age group < 45 years with 43.2%.

Fever was found in (93.8%) patients, followed by general weakness & fatigue in (85.2%), sleep disorders in (84.0%), and muscular ache in (79.0%).

Among comorbid conditions diabetes mellitus was found as most common in (16.0%) patients.

Conclusion: The most common ENT manifestations were anosmia-dysgeusia with sore throat and pharyngeal erythema.

Key words: ENT manifestations, general symptoms, comorbid diseases, Covid-19, Aden.

INTRODUCTION

Since the first documented case of pneumonia of unknown origin hailed from Wuhan city, Hubei province, China, back in December 2019, the novel SARS-CoV-2 leading to Covid-19 has swept across the globe afflicted the people in every corner. As of 21 March 2021, the total case number has culminated to over 122 million worldwide, with a mortality rate of 2.2% [1].

11 March 2021 marks the first anniversary since WHO declared the Covid-19 outbreak a pandemic. With the vaccine challenges that lie ahead, the light at the end of the tunnel remains elusive.

We learnt that the transmission routes are via respiratory droplet, aerosols and by contact that may be indirect, which succinctly impose a remarkably high risk to the head and neck surgeons who often deal with aerosol-generating procedures.

In fact, the first doctor who succumbed to Covid-19 in Wuhan was an otolaryngologist [2]. The Covid-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing viral pandemic that emerged from the city of Wuhan, China and quickly spread to the rest of the world [3]. This outbreak has been responsible for nearly 935,000 deaths worldwide and more than 29 million people have been confirmed as infected so far [4]. The virus is transmitted from human to human via droplet transmission and direct contact with oral, nasal, and eye mucous membranes [5]. Studies suggest that Covid-19 may become airborne through aerosolgenerating clinical procedures [6].

Coronaviruses are known to cause diseases of varying severity affecting respiratory, neurological, gastrointestinal, and hepatic organs in animals and humans [6].

According to the clinical reports from Asia, the most frequently observed symptoms are cough, fever, sputum production, dyspnea, arthralgia, myalgia, rhinorrhea, sore throat, headache, and diarrhea [7].

The above-mentioned symptoms have been reported and they are the most common findings for Covid-19; however, several studies, particularly from Europe, have also reported certain chemosensory dysfunction symptoms such as anosmia and ageusia, which are common in Covid positive patients [8].

The virus is thought to be transmitted via aerosols produced during sneezing, coughing, or talking with infected people [9].

Preventive measures such as use of masks and thorough cleaning of hands, clothes, and shoes, and maintaining social distance can break the chain of transmission [10].

Objectives

To study and document the ENT manifestations of covid-19 infection of patients in Aden, Yemen

MATERIALS AND METHOD

This was a retrospective descriptive study, in which we reviewed the medical records of 81 patients with Covid-19 seen at *Covid-*19 Treatment Center at Al-Gamhoria Teaching Hospital in Aden during the period April 2020 to March 2021.

The patients' charts were retrieved and information about sex, age, ENT manifestations, general symptoms and comorbid conditions were obtained. SPSS program, version 17, was used to analyze the data. The continuous data are presented as means and categorical variables are presented as frequencies and percentages. The Fisher test was used to determine whether the difference between means and values are significant. A p-value <0.05 was considered statistically significant.

RESULTS

Out of 81 patients, 52 patients were males (64.2%) and 29 patients (35.8%) were females and the mean age was 40.2 ± 13.9 years. The mean age of male patients was 41.8 ± 13.6 years while for females was 37.3 ± 14.5 years. The age ranged between 18 to 66 years; the association between means is statistically significant. In addition, the age group < 45 years represented 59.3% while the age group 45 and more represented 40.7%; as shown in Table 1 and Figure 1.

Table 1: Demographic variables of the study patients (no = 81)

Variables	No	%	
Sex:			
Males	52	64.2	
Females	29	35.8	
Age range (years):	18 - 66		
Mean age (all patients):	40.2 ± 13.9		
Mean age (males):	41.8±13.6		
Mean age (females):	37.3±14.5		
p-value	0.025		
Age groups (years):			
< 45	48	59.3	
≥45	33	40.7	




Table 2 & Figure 2 reveal the distribution ofENT manifestations related to sex of the

study patients. Anosmia-dysgeusia with sore throat and pharyngeal erythema, were the most common ENT manifestations, 77.8%, and 77.8% respectively,

followed by the non- ENT manifestations headache 74.1% and cough 51.8%,

breathing difficulty 34.6%, odynophagia 28.4%, nasal discharge 25.9%, and nasal congestion 24.7%.

Less than these of ENT percent manifestations presented as nasal 17.3, obstruction oropharyngeal ulcer 16.0%, tinnitus 9.8%, epistaxis 8.6%, vertigo 8.6%, hearing loss 7.4% and ear pain and itching 7.4%.

The analysis of demographic factors as shown in Table 2 indicates the influence of gender on the occurrence of individual ENT symptoms. The male patients had a higher probability of developing ENT manifestations.

The relation between anosmia-dysgeusia and sex was statistically significant (p < 0.05), while the rest of ENT manifestations were not statistically significant with sex.

Variables	Sex		Total No (%)	P-value		
	Females No (%)		Males No (%)			
Anosmia-dysgeusia:		, /				
Yes	27	(33.3)	36	(44.4)	63	P=0.011
No	2	(2.5)	16	(19.8)	(77.8)	
	_	()		(18	
					(22.2)	
Sore throat & pharyngeal erythema:					(22.2)	
Yes	26	(32.1)	37	(45.7)	63	P =
No	3	(3.7)	15	(18.5)	(77.8)	0.047
NO	5	(3.7)	15	(18.5)		0.047
					18 (22.2)	
Headache:					(22.2)	
	20	(0 1 7)	10	(40.4)	<i>c</i> 0	D. 0.05
Yes	20	(24.7)	40	(49.4)	60	P > 0.05
No	9	(11.1)	12	(14.8)	(74.1)	
					21	
			L		(25.9)	
Cough:						
Yes	15	(18.5)	27	(33.3)	42	P > 0.05
No	14	(17.3)	25	(30.9)	(51.8)	
					39	
					(48.2)	
Breathing difficulty:						
Yes	9	(11.1)	19	(23.5)	28	P > 0.05
No	20	(24.7)	33	(40.7)	(34.6)	
		× /			53	
					(65.4)	
Odynophagia:						
Yes	7	(8.6)	16	(19.8)	23	P > 0.05
No	22	(27.2)	36	(44.4)	(28.4)	
1.0		(_/)	20	()	58	
					(71.6)	
Nasal discharge:					(/110)	
Yes	7	(8.6)	14	(17.3)	21	P > 0.05
No	22	(27.2)	38	(46.9)	(25.9)	1 > 0.05
10	22	(27.2)	50	(40.7)	60	
					(74.1)	
Nasal congestion:	1		<u> </u>		(,)	
Yes	8	(9.9)	12	(14.8)	20	P > 0.05
No	21	(25.9)	40	(49.4)	(24.7)	1 > 0.05
NO	21	(23.9)	40	(49.4)	61	
					(75.3)	
Nasal obstruction:					(13.3)	
Yes	6	(7.4)	8	(9.9)	14	P > 0.05
No	23	(7.4) (28.4)	8 44	(54.3)	(17.3)	1 / 0.05
110	23	(20.4)	44	(34.3)		
					67	
Ononhamma ogl ul					(82.7)	
Oropharyngeal ulcer:	4	(4.0)	0	(11.1)	12	D 0.05
Yes	4	(4.9)	9	(11.1)	13	P > 0.05
No	25	(30.9)	43	(53.1)	(16.0)	
					68	
					(84.0)	

Table 2: Distribution of ENT manifestations related to sex of the study patients (n=81)

Table 2 To Be Continued						
Tinnitus:						
Yes	1	(1.2)	7	(8.6)	8	P > 0.05
No	28	(34.6)	45	(55.6)	(9.8)	
					73	
					(90.1)	
Epistaxis:						
Yes	1	(1.2)	6	(7.4)	7	P > 0.05
No	28	(34.6)	46	(56.8)	(8.6)	
					74	
					(91.4)	
Vertigo:						
Yes	3	(3.7)	4	(4.9)	7	P > 0.05
No	26	(32.1)	48	(59.3)	(8.6)	
					74	
					(91.4)	
Hearing loss:						
Yes	1	(1.2)	5	(6.2)	6	P > 0.05
No	28	(34.6)	47	(58.0)	(7.4)	
					75	
					(92.6)	
Ear pain and itching:						
Yes	1	(1.2)	5	(6.2)	6	P > 0.05
No	28	(34.6)	47	(58.0)	(7.4)	
					75	
					(92.6)	

Figure 2: Distribution of ENT manifestations related to sex of the study patients




Table 3 & Figure 3 illustrate the distribution of ENT manifestations related to age groups of the study patients.

We found the manifestation of anosmiadysgeusia more common among patients of the age group <45 years with 43.2%, additionally sore throat & pharyngeal erythema and headache more common in patients of the age group <45 years with 46.9% and 45.7% respectively.

While cough and breathing difficulty more common in patients of the age group \geq 45 years with 34.6% and 30.9% respectively.

Then there is agreement and differences in the ENT manifestation rates between the

two age groups less than 45 years, as well as 45 years and more.

The analysis of age factors as shown in Table 3 indicates the influence of age on the occurrence of individual ENT symptoms. The age group < 45 years old have a higher probability of developing anosmia-dysgusia, sore throat & pharyngeal erythmia, headache, nasal discharge, nasal congestion and nasal obstruction

The relation between cough, breathing difficulty, epistaxis and vertigo with age groups was statistically significant (p < 0.05), while the rest of ENT manifestations were not statistically significant with age groups.

Variables	Age group (year		Total	P-value
, ur mores	< 45	≥ 45		1 (1111)
	No (%)	No (%)	No (%)	
Anosmia-dysgusia:				
Yes	35 (43.2)	28 (34.6)	63 (77.8)	P > 0.05
No	13 (16.0)	5 (6.2)	18 (22.2)	
S. throat & ph. erythmia:				
Yes	38 (46.9)	25 (30.9)	63 (77.8)	P > 0.05
No	10 (12.3)	8 (9.9)	18 (22.2)	
Headache:				
Yes	37 (45.7)	23 (28.4)	60 (74.1)	P > 0.05
No	11 (13.6)	10 (12.3)	21 (25.9)	
Cough:				
Yes	14 (17.3)	28 (34.6)	42 (51.9)	P = 0.000
No	34 (42.0)	5 (6.2)	39 (48.1)	
Breathing difficulty:				
Yes	3 (3.7)	25 (30.9)	28 (34.6)	P = 0.000
No	45 (55.5)	8 (9.9)	53 (65.4)	
Odynophagia:				
Yes	12 (14.8)	11 (13.6)	23 (28.4)	P > 0.05
No	36 (44.4)	22 (27.2)	58 (71.6)	
Nasal discharge:				
Yes	15 (18.5)	6 (7.4)	21 (25.9)	P > 0.05
No	33 (40.7)	27 (33.3)	60 (74.1)	
Nasal congestion:				
Yes	11 (13.6)	9 (11.1)	20 (24.7)	P > 0.05
No	37 (45.7)	24 (29.5)	61 (75.3)	
Nasal obstruction:				
Yes	9 (11.1)	5 (6.2)	14 (17.3)	P > 0.05
No	39 (48.1)	28 (34.6)	67 (82.7)	
Oropharyngeal ulcer:				
Yes	5 (6.2)	8 (9.9)	13 (16.0)	P > 0.05
No	43 (53.1)	25 (30.9)	68 (84.0)	
Tinnitus:			0 (0.0)	D 0.0-
Yes	3 (3.7)	5 (6.2)	8 (9.9)	P > 0.05
No	45 (55.6)	28 (34.6)	73 (90.1)	
Epistaxis:	1 (1.0)	(7)	7 (0.0)	D 0.017
Yes	1 (1.2)	6 (7.4)	7 (8.6)	P = 0.017
No	47 (58.0)	27 (33.4)	74 (91.4)	
Vertigo:	1 (1.2)	6 (7.4)	7 (8.6)	D 0.017
Yes	1 (1.2)	6 (7.4) 27 (22.4)		P-0.017
No Hanning Lang	47 (58.0)	27 (33.4)	74 (91.4)	
Hearing loss:	2 (25)	4 (4.0)	6 (7.4)	D > 0.05
Yes	2(2.5)	4 (4.9)	6 (7.4)	P > 0.05
No	46 (56.8)	29 (35.8)	75 (92.6)	
Ear pain and itching:	2 (2.5)	4 (1.0)	(7.4)	D: 0.05
Yes	2(2.5)	4 (4.9)	6 (7.4)	P > 0.05
No	46 (56.8)	29 (35.8)	75 (92.6)	

 Table 3: Distribution of ENT manifestations related to age groups of the study patients (n=81)

S. throat & ph. erythmia = Sore throat & pharyngeal erythmia






Table 4 summarizes the frequency of general symptoms. Fever was found in 76 (93.8%) patients, followed by general weakness & fatigue in 69 (85.2%), sleep disorders in 68 (84.0%), muscular ache in 64 (79.0%) and loss of appetite in 54 (66.7%). Nausea and vomiting, was observed in 34 (42.0%) patients, diarrhea in 34 (42.0%) patients, abdominal pain in 21 (25.9%) and skin rash in 3 (3.7%) patients.

Table 4:	Frequency	of general	symptoms	s (no = 81)


Variables	No	%
Fever:		
Yes	76	93.8
No	5	6.2
General weakness & fatigue:		
Yes	69	85.2
No	12	14.8
Sleep disorders:		
Yes	68	84.0
No	13	16.0
Muscular ache:		
Yes	64	79.0
No	17	21.0
Loss of appetite:		
Yes	54	66.7
No	27	33.3
Nausea and vomiting:		
Yes	34	42.0
No	47	58.0
Diarrhea:		
Yes	34	42.0
No	47	58.0
Abdominal pain:		
Yes	21	25.9
No	60	74.1
Skin rash:		
Yes	3	3.7
No	78	96.3

Among comorbid conditions diabetes mellitus (DM) was found as most common in 13 (16.0%) patients followed by hypertension in 7 (8.6%) patients and liver diseases in 1 (1.2%) patient; as shown in Table 5 and Figure 4.

Table 5: Distribution of comorbid conditions among the study patients

Variables	No	%
Comorbid conditions:		
Diabetes mellitus (DM)	13	16.0
Hypertension	7	8.6
Liver disease	1	1.2
None	60	74.2
Total	81	100

Figure 4: Percentage of comorbid diseases among the study patients



DISCUSSION

Symptomatology of Covid-19 is diverse; clinically, it ranges from asymptomatic to mild upper respiratory tract infection (URTI)-like symptoms to a*cute respiratory distress syndrome* (ARDS) to multiorgan dysfunction [11]. Most common symptoms include fever, cough, sore throat, headache, fatigue, myalgia, and breathlessness, [12,13,14] due to which Covid-19 infection become indistinguishable from other upper respiratory infections.

Our present study found 81 patients with Covid-19 during one year of the study period and they were 52 (64.2%) males and 29 (35.8%) females with a ratio male to female 1.8:1.

The mean age of male patients was 41.8 ± 13.6 years while for females was 37.3 ± 14.5 years. The age ranged between 18 to 66 years; the association between means is statistically significant. In addition, the age group < 45 years represented 59.3% while the age group 45 and more represented 40.7%.

Borah et al [15] reported that, a total of 2000 laboratory confirmed cases were included in their study and out of these (58%) were males and (42%) were females. They added that Covid-19 disease has rapidly spread across the whole world. Otorhinolaryngologists are at high risk due to the close contact with the mucus membrane of the upper respiratory tract.

A study conducted in Turkey [16] reported that a total of 116 patients consisting of (50%) males and (50%) females were included in their study. The mean age of the patients was 57.24 ± 14.32 years and the age ranged between 19 and 83 years. The patients were grouped in terms of age, where (53.4%) were under the age of 60 years, and (46.6%) were in the group over 60 years. There was no statistical difference in terms of gender and mean age between groups (p > 0.05).

In our present study we found anosmiadysgeusia and sore throat + pharyngeal erythema, were the most common ENT manifestations, 77.8%, and 77.8% respectively, followed by headache 74.1% and cough 51.8%, breath difficulty 34.6%, odynophagia 28.4%, nasal discharge 25.9%, and nasal congestion 24.7%.

Less than these percent of ENT manifestations presented as nasal obstruction 17.3. oropharyngeal ulcer 16.0%, tinnitus 9.8%, epistaxis 8.6%. vertigo 8.6%, hearing loss 7.4% and ear pain and itching 7.4%.

The relation between anosmia-dysgeusia and sex was statistically significant (p <0.05), while the rest of ENT manifestations were not statistically significant with sex.

El-Anwar et al [17] from Egypt reported in their study, that the most frequently ENT manifestations were sore throat in (30%) patients, nasal congestion in (28.3%) patients, nasal obstruction in (26.7%) patients, sneezing in (26.6%) patients, headache in (25%) patients, olfactory and taste dysfunction in (25%) patients, and runny nose or rhinorrhea in (20%) patients.

Srivastava et al [18] mentioned that the majority (66.5%) of the cases had sore throat, followed by cases of nasal congestion (54.1%). Breathing difficulty was present in (41.7%) cases, and dry cough (37.1%). This finding is to some extent consistent with our study findings.

Different studies [19,20,21] reported that the disease can manifest in the form of various symptoms, such as fever, cough, breathing difficulty, fatigue, myalgia, rhinorrhea, and disturbances in the sense of smell and taste. In the later stages of the disease, symptoms of pneumonia, acute respiratory distress syndrome (ARDS), and respiratory failure have been also reported.

Srivastava et al [18] reported from North India that the results of their study showed that the most common presentation was sore throat with (66.46%) followed by nasal congestion with (54.14%). Patients also presented with breathing difficulty (41.71%) and dry cough (37.07%). Few patients also complained of alteration of the sense of smell and taste with (1.76%).

According to the report by Dagur et al [22], common symptoms of Covid-19 are high grade fever, tiredness, and dry cough. A meta-analysis by Krajewska et al [23] demonstrated that, in the Chinese studies, fever and dry cough were frequently encountered symptoms, whereas in Australian studies, rhinorrhea and dyspnea were commonly seen. Studies from South Korea, Italy, China, and Germany reported hyposmia and anosmia as frequently encountered symptoms [23].

A study conducted in India [24] found the most common ENT manifestations for Covid-19 were loss of smell and taste sensation (26%), sore throat (47.2%), hearing loss (54.4%) and headache (37.8%). In the current study we found the manifestation of anosmia-dysgeusia more common among patients of the age group <45 years with 43.2%, additionally sore throat & pharyngeal erythema and headache more common in patients of the age group years with 46.9% and <45 45.7% respectively. In addition. cough and breathing difficulty were found more common in patients of the age group ≥ 45 years with 34.6% and 30.9% respectively. Then there is agreement and differences in the rest of ENT manifestation rates between the two age groups less than 45 years, as well as 45 years and more.

The relation between cough, breathing difficulty, epistaxis and vertigo with age groups was statistically significant (p < 0.05), while the rest of ENT manifestations were not statistically significant with age groups.

Savtale et al [24] reported in their study that hyposmia/anosmia and ageusia were both sudden in onset and had a higher frequency in younger population.

In our present study, we found fever in (93.8%) patients, followed by general weakness & fatigue in (85.2%) patients, sleep disorders in (84.0%) patients, muscular ache in (79.0%) patients and loss of appetite in (66.7%) patients. Nausea and vomiting were observed in (42.0%) patients, diarrhea in (42.0%) patients, abdominal pain in (25.9%) and skin rash in (3.7%) patients.

A published study reported that the most common symptoms with which these patients presented were fever (93%) and cough (85%) and the least common symptoms were malaise, generalized bodyache and abdominal symptoms like diarrhea [15].

According to studies conducted previously [25,26], it was found that non-ENT manifestations like fever are more common in Covid patients than ENT manifestations. These symptoms are more commonly seen during the early stages of the disease [27].

In previous studies [28,29], fever was the most common symptom, reported to affect up to 92.8% of patients, followed by cough (69.8%), dyspnea (34.5%), myalgia (27.7%), headache (7.2%), and diarrhea (6.1%).

In the present study, we found diabetes mellitus as most common comorbid disease in (16.0%) patients followed by hypertension in (8.6%) patients and liver diseases in (1.2%) patient.

A study conducted in China by Guan et al [30] reported that of the 1590 cases of Covid-19, (25.1%) reported having at least one comorbidity. The prevalence of specific comorbidities were: hypertension (16.9%), cardiovascular diseases other (53.7%)cerebrovascular diseases (1.9%), diabetes (8.2%), hepatitis B infections (1.8%). obstructive pulmonary chronic disease (1.5%), chronic kidney diseases (1.3%), malignancy (1.1%) and immunodeficiency (0.2%).

In this study, 25.8% of the patients had comorbid diseases and it was higher than the findings of the study conducted in China 15.8% [31] and similar to the finding conducted in Tailand 25.0% [32] and Singapore 28.3% [33].

In the current study, diabetes mellitus and hypertension were the most common comorbidities and these results supported the findings of the earlier studies conducted in hospitalized Covid-19 patients [34,35,36].

CONCLUSION

The most common ENT manifestations for Covid-19 in our current study were anosmia-dysgeusia with sore throat and pharyngeal erythema, followed by headache, cough breathing difficulty. ENT manifestations are not always the same in Covid-19 patients. They may vary with age, sex and comorbid conditions. Further studies are needed to determine and to evaluate this health problem in our country.

Conflict of Interest: None

Ethical Approval: Approved

REFERENCES

- World Health Organization: weekly epidemiological update on Covid-19 – 21 March 2021. Available at: https://www.who.int/publications/m/item/ weekly- epidemiological- update.
- Kulcsar MA, Montenegro FL, Arap SS, et al. High risk of Covid-19 infection for head and neck surgeons. Int Arch Otorhinolaryngol. 2020; 24:e129–e130.
- Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708– 1720.
- 4. Johns Hopkins University and Medicine. Coronavirus resource center. 2020. Available on: https://coronavirus.jhu.edu/.
- Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 2020; 18:360– 362.
- 6. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a

man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.

- Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323: 1488–1494.
- Roland LT, Gurrola JG, Loftus PA, et al. Smell and taste symptom-based predictive model for Covid-19 diagnosis. Int Forum Allergy Rhinol. 2020; 10: 832–838.
- 9. European Rhinologic Society(2020). [Internet]. 2020 Available from:https://www.researchgate.net/publicati on/340848609_Nasal_Pharyngeal_and_Lary ngeal_Endoscopy_Procedures_during_Covi d-19_Pandemic_ Available_Recommendations_from_Nation

al_and_International_Societies.

- Islam MS, Rahman KM, Sun Y, et al. Current knowledge of COVID-19 and infection prevention and control strategies in healthcare settings: A global analysis. Infect Control Hosp Epidemiol. 2020 May 15 : 1– 11
- Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E. Clinical, laboratory and imaging features of Covid-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020; 34: 101623.
- 12. Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation and treatment coronavirus (Covid-19). Statpearls 2020. Available on: http://www.ncbi.nlm.nih.gov/pubmed/32150 360
- Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (Covid-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3): 105924.
- Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of respiratory viral infections. Annu Rev Virol 2020; 7(1): 83–101.
- Borah H, Das S, Goswami A. Otorhinolaryngological Manifestations and Its Management in Covid-19 Patients. Indian J Otolaryngol Head Neck Surg. 2021; 1-4. Available at: https://doi.org/10.1007/s12070-021-02436-9
- Korkmaz MO, Egilmez OK, Ozcelik MA, et al. Otolaryngological manifestations of hospitalised patients with confirmed Covid-19 infection. Eur Arch Otorhinolaryngol. 2021; 278(5): 1675-1685

- 17. El-Anwar MW, Eesa M, Mansour W, et al. Analysis of Ear, Nose and Throat Manifestations in Covid-19 Patients. Int Arch Otorhinolaryngol 2021;25(3):e343– e348.
- Srivastava A, Agarwal AC, Alam SZ. ENT Manifestation in patients suffering from Covid-19: Study from a Covid Hospital in North India. Int Arch Otorhinolaryngol. 2022; 26(1): e148-e151.
- 19. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ. 2020; 368: m1036.
- Lescure FX, Bouadma L, Nguyen D. Clinical and virological data of the first cases of Covid-19 in Europe: a case series. Lancet Infect Dis. 2020;20(06): 697– 706.
- 21. Mohfw.gov.in.2020. Mohf/Home[online]. [Available at: https://www.mohfw.gov.in/index.html
- 22. Dagur H S, Dhakar S. Genome Organization of Covid-19 and Emerging Severe Acute Respiratory Syndrome Covid-19 Outbreak: A Pandemic. EJMO. 2020; 4(02):107–115.
- Krajewska J, Krajewski W, Zub K, et al. Covid-19 in otolaryngologist practice: a review of current knowledge. Eur Arch Otorhinolaryngol. 2020; 277(07): 1885– 1897.
- 24. Savtale S, Hippargekar P, Bhise S, et al. Prevalence of otorhinolarygological symptoms in Covid-19 patients. Indian J Otolaryngol Head Neck Surg. 2021; 8: 1-7
- 25. Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (Covid-19) implicate special control measures. J Med Virol. 2020; 92(6):568–

576. https://doi.org/10.1002/jmv.25748 26. Li LQ, Huang T, Wang YQ, et al. Covid-19

- 26. Li LQ, Huang T, wang YQ, et al. Covid-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92(6):577–583.
- 27. Vaira L, Salzano G, Deiana G, et al. Anosmia and ageusia: common findings in COVID -19 patients. Laryngoscope. 2020; 130(7):1787
- Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (Covid-19): the epidemic and the

challenges. Int J Antimicrob Agents 2020; 55(3): 105924.

- Tian S, Hu N, Lou J, et al. Characteristics of Covid-19 infection in Beijing. J Infect 2020; 80(4): 401–406.
- 30. Guan W-j, Liang W-h, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020; 55: 2000547. https://doi.org/10.1183/ 13993003.00547-2020
- 31. Li Y, Shi J, Xia J, et al. Asymptomatic and symptomatic patients with non-severe coronavirus disease (Covid-19) have similar clinical features and virological courses: a retrospective single center study. Front Microbiol. 2020. https://doi.org/10.3389/fmicb.2020.01570.
- 32. Pongpirul WA. Wiboonchutikul S. Charoenpong L. Clinical course and potential predictive factors for pneumonia of adult patients with Coronavirus Disease (Covid-19): retrospective 2019 а observational analysis of 193 confirmed cases in Thailand. PLoS Negl Trop Dis. 2020;14(10): e0008806. https://doi.org/10. 1371/journal.pntd.0008806
- 33. Puah SH, Young BE, Chia PY, et al. Clinical features and predictors of severity in Covid-19 patients with critical illness in Singapore. Sci Rep. 2021;11(1):7477.

https://doi.org/10.1038/ s41598-021-81377-3.

- Vaughan L, Veruttipong D, Shaw JG, et al. Relationship of socio-demographics, comorbidities, symptoms and healthcare access with early Covid-19 presentation and disease severity. BMC Infect Dis. 2021;21(1):40. https://doi.org/10.1186/ s12879-021-05764-x.
- 35. Sacco V, Rauch B, Gar C, et al. Overweight/obesity as the potentially most important lifestyle factor associated with signs of pneumonia in Covid-19. PLoS ONE 2020;15(11):e0237799. Available at: https://doi.org/10.1371/journal.pone.023779 9
- 36. Feng Z, Yu Q, Yao S, et al. Early prediction of disease progression in Covid-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020;11(1):4968.

How to cite this article: Saleh Mohamed Abobaker Alshaiby. Study the ENT manifestations of Covid-19 patients, Aden, Yemen. International Journal of Science & Healthcare Research. 2022; 7(4): 192-201. DOI: https://doi.org/10.52403/ ijshr.20221027
